We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies. Read more: https://t.co/x41THO0uSH

This submission follows the FDA's review of additional data and represents an important regulatory step in expanding potential treatment options for adult patients with BCG-unresponsive NMIBC with papillary disease. Read more: https://t.co/bIGkDzqhSQ

Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific & Medical Officer of ImmunityBio, joined @NewsNation’s Cuomo Special Edition to discuss the scientific and systemic challenges behind curing cancer as well as the path forward through innovation in

WATCH: New approaches to fighting cancer are shifting focus toward boosting the immune system. Dr. Patrick Soon-Shiong explains how AI-engineered antibodies could redefine treatment.

ImmunityBio will host a live conference call at 1:30 p.m. PT (4:30 p.m. ET) on Tuesday, March 3, 2026, to provide a business update, discuss progress across our clinical trial pipeline, and review financial results for the year ended December 31, 2025. Participants can join via

ImmunityBio has completed enrollment in our pivotal randomized Phase 2 trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus BCG versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The FDA-requested interim

During his presentation at the “Cancer 2035: A Roadmap for the Future” Summit hosted by the @MilkenInstitute and the @nixonfoundation, Dr. Patrick Soon-Shiong discussed the central role of coordinated innate and adaptive immune activation in cancer therapy. By leveraging

At ImmunityBio, we're pioneering immunotherapies to transform the path of complex cancers, aiming to bring better, more meaningful outcomes for patients. Explore the science behind the future we're building: https://t.co/w3w5XZusZ4

We are pleased to share that Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio will participate as a featured speaker at the "Cancer 2035: A Roadmap for the Future" Summit hosted by the @MilkenInstitute and the

We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer. With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access

The cancer journey is shaped not only by the treatment, but by those who provide care alongside it. Caregivers play a vital role in supporting patients as they navigate complex decisions and endure both the physical and emotional demands of their disease. Their presence shapes

ImmunityBio is forging new ground in the Middle East with a regional office in Saudi Arabia and a commercial partnership with Biopharma Cigalah. This initiative supports clinicians and health systems throughout the Middle East and North Africa, furthering our mission to extend

We're advancing global access to ANKTIVA®. A new distribution partnership with Accord Healthcare and the launch of an Irish subsidiary will expand commercialization efforts across ~30 countries, bringing this important therapy closer to eligible patients with BCG-unresponsive

The European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. This decision broadens availability across 33

Roger Stone interviews ImmunityBio Founder, Executive Chairman, and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong on Anktiva. Dr. Patrick discusses IL-15’s role in activating natural immune cells, its impact in bladder cancer and lymphopenia, and regulatory

As a company that believes medicine should not only treat but transform lives, we pursue outcomes that matter. Our team is deeply connected to this mission, many of us driven by personal experiences that fuel our commitment. In every breakthrough, there is a shared drive to

Glioblastoma presents significant scientific and clinical challenges for patients and healthcare providers. The disease's limited treatment options emphasize the need for continued research and deeper scientific understanding. Our efforts in the glioblastoma space are focused on